en پژوهشی اصيل Original Research <span style="font-size:11pt"><span style="text-justify:inter-ideograph"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><strong><span style="font-size:9.0pt"><span style="background:white"><span cambria="" style="font-family:"><span style="color:#1f497d">Aims</span></span></span></span></strong><b><span style="font-size:9.0pt"><span cambria="" style="font-family:"><span style="color:#1f497d">:</span></span></span></b><b> </b><span style="font-size:9.0pt"><span cambria="" style="font-family:"><span style="color:black">Different corticosteroids with different characteristics, such as hydrocortisone and <a name="_Hlk136388312">dexamethasone</a>, have been used to treat exacerbated chronic obstructive pulmonary disease, but the drug of choice is unclear. The main goal of the present study was to compare the efficacy of hydrocortisone and dexamethasone on clinical symptoms, peak expiratory flow, oxidative stress factors, and inflammatory mediators in patients with exacerbation of chronic obstructive pulmonary disease.</span></span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="text-justify:inter-ideograph"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:9.0pt"><span cambria="" style="font-family:"><span style="color:#1f497d">Materials & Methods:</span></span></span></b><span style="font-size:9.0pt"><span cambria="" style="font-family:"><span style="color:black"> In this single-blind randomized clinical trial study in 2021, 70 eligible patients with chronic obstructive pulmonary disease exacerbations were selected and randomly divided into two A (8mg of intravenous dexamethasone daily) and B (200mg of intravenous daily hydrocortisone) groups. Clinical symptoms and <span style="background:white">peak expiratory flow were measured before intervention (day 1), after intervention (day 2), and on discharge day. However, oxidative stress factors and inflammatory mediators </span>were evaluated on day one and discharge day. Moreover, the probable complications of both drugs were measured and scaled 1-4 by the researcher. </span></span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="text-justify:inter-ideograph"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:9.0pt"><span cambria="" style="font-family:"><span style="color:#1f497d">Findings:</span></span></span></b><b> </b><span style="font-size:9.0pt"><span cambria="" style="font-family:"><span style="color:black">B</span></span></span><span style="font-size:9.0pt"><span cambria="" style="font-family:"><span style="color:black">etween groups, comparisons showed significant differences in the </span></span></span><span style="font-size:9.0pt"><span cambria="" style="font-family:"><span style="color:black">patients&rsquo;</span></span></span><span style="font-size:9.0pt"><span cambria="" style="font-family:"><span style="color:black"> clinical indicators for shortness of breath (p=0.02), sputum volume (p=0.01), and oxygen saturation of arterial blood (p=0.02).</span></span></span><span style="font-size:9.0pt"><span cambria="" style="font-family:"><span style="color:black"> However, </span></span></span><span style="font-size:9.0pt"><span cambria="" style="font-family:"><span style="color:black">these differences were related to the first day, and no statistically significant differences were observed on the second or discharged days. The intragroup comparison revealed that the prescription of both dexamethasone and hydrocortisone led to significant improvement in the </span></span></span><span style="font-size:9.0pt"><span cambria="" style="font-family:"><span style="color:black">patient&rsquo;s</span></span></span><span style="font-size:9.0pt"><span cambria="" style="font-family:"><span style="color:black"> clinical symptoms</span></span></span><span style="font-size:9.0pt"><span cambria="" style="font-family:"><span style="color:black">. </span></span></span><span style="font-size:9.0pt"><span cambria="" style="font-family:"><span style="color:black"></span></span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="text-justify:inter-ideograph"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:9.0pt"><span cambria="" style="font-family:"><span style="color:#1f497d">Conclusion:</span></span></span></b><b> </b><span style="font-size:9.0pt"><span cambria="" style="font-family:"><span style="color:black">Dexamethasone and Hydrocortisone are the same in improving important clinical symptoms and have similar efficacy on inflammation and oxidative stress in patients with COPD exacerbation. &nbsp;</span></span></span></span></span></span></span><br> &nbsp; Pulmonary Disease,Chronic Obstructive,Dexamethasone,Hydrocortisone, 63 69 http://jccs.yums.ac.ir/browse.php?a_code=A-10-216-1&slc_lang=en&sid=1 A. Hosseini danaei.nazanin@gmail.com 10031947532846004588 10031947532846004588 No Department of Internal Medicine, Yasuj University of Medical Sciences, Yasuj, Iran A. H. Doustimotlagh amirhosseindoustimotlagh@gmail.com 10031947532846004589 10031947532846004589 No Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran A. Afrasiabifar afrasiabifar@yahoo.com 10031947532846004590 10031947532846004590 No School of Nursing and Midwifery, Yasuj University of Medical Sciences, Yasuj, Iran S. Sedaghattalab moslem.sedaghattalab@gmail.com 10031947532846004591 10031947532846004591 Yes Department of Internal Medicine, Yasuj University of Medical Sciences, Yasuj, Iran